Baxter BioScience Starts Construction of $50 Million Expansion At Their Thousand Oaks, California Campus

---

Researched by Industrialinfo.com (Industrial Information Resources, Inc.; Houston, Texas) Baxter Healthcare Corporation's (NYSE: BAX) (Deerfield, Illinois) BioScience division has begun site work on their fourth hemophilia therapy production suite in Thousand Oaks, California. Estimated to cost $50 million, the new production line will be known as `Suite D` when it is completed and comes online in 2004.

Baxter BioScience's Thousand Oaks facility manufactures recombinant Antihemophilic Factor (rAHF), which is a clotting factor produced by recombinant DNA technology and used as a treatment for the blood disorder hemophilia. Baxter has just received FDA approval on Suite C, a third production suite that was completed earlier this year. Suite C had been in full production prior to the FDA notification, having already received European regulatory approval. Global demand for hemophilia therapy has doubled since 1985, due in part to increased preventive treatment. Baxter has increased its North American rAHF capacity every year since its introduction in 1992 and anticipates a global capacity of two billion units of rAHF by 2005.

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Incorporated. Baxter is a global medical products and services company that provides treatment therapies for people with life-threatening conditions in more than 100 countries. Baxter employs over 45,000 employees and had $6.9 billion in total sales for 2000.